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Abstract
Background: It has been estimated that Nursing Home (NH) residents with impaired cognitive status receive an average of
seven to eight drugs daily. The aim of this study was to determine prevalence and factors associated with use of
inappropriate drugs in elderly patients with severe cognitive impairment living in NH in Europe.
Methods: Cross-sectional data from a sample of 1449 NH residents with severe cognitive impairment, participating in the
Services and Health for Elderly in Long TERm care (SHELTER) study were analysed. Inappropriate drug use was defined as
the use of drugs classified as rarely or never appropriate in patients with severe cognitive impairment based on the Holmes
criteria published in 2008.
Results: Mean age of participating residents was 84.268.9 years, 1087 (75.0%) were women. Inappropriate drug use was
observed in 643 (44.9%) residents. Most commonly used inappropriate drugs were lipid-lowering agents (9.9%), antiplatelet
agents (excluding Acetylsalicylic Acid – ASA –) (9.9%), acetylcholinesterase, inhibitors (7.2%) and antispasmodics (6.9%).
Inappropriate drug use was directly associated with specific diseases including diabetes (OR 1.64; 95% CI 1.21–2.24), heart
failure (OR 1.48; 95% CI 1.04–2.09), stroke (OR 1.43; 95% CI 1.06–1.93), and recent hospitalization (OR 1.69; 95% CI 1.20–2.39).
An inverse relation was shown between inappropriate drug use and presence of a geriatrician in the facility (OR 0.55; 95% CI
0.39–0.77).
Conclusion: Use of inappropriate drugs is common among older EU NH residents. Determinants of inappropriate drug use
include comorbidities and recent hospitalization. Presence of a geriatrician in the facility staff is associated with a reduced
rate of use of these medications.
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Introduction
Dementia is a common condition in institutionalized older adults:
it has been estimated that in the United States (US) 50% of Nursing
Home(NH)residentshaveadiagnosisofdementiaandthemajorityof
them are affected by other chronic diseases [1]. In this population,
dementia represents a life-defining disease, in which many physical
and psychological symptoms proceeded by a prolonged terminal
phasemight influencequalityof life. In this context, aphysician’s care
plan shifts from a curative approach to symptoms management.
Notably, NH residents with impaired cognitive status receive an
averageof seven to eightdrugsdaily [2],whichareoftenprescribed to
treat chronic conditions rather than to manage symptoms, with
questionable benefits to the patients [3].
Use of drugs in older adults with cognitive impairment raises
several potential concerns. In particular, several studies have
emphasized the need to avoid drugs that may affect cognition or
induce delirium when treating patients with co-existing cognitive
impairment [4]. In addition, memory loss, decline in intellectual
function and impaired judgment and language, commonly
observed in patients with advanced dementia, have obviously
negative impact on decision making capacity, influence treatment
adherence, and may cause communication difficulties including
a decreased ability to report adverse effects [5,6]. For this reason
the use of drugs to treat non-dementia illnesses in older adults with
severe cognitive impairment might be questionable and may lead
to serious adverse effects, even when clearly beneficial drugs
recommended by clinical guidelines are prescribed [5]. These
concerns represent barriers to pharmacological treatment of
complex patients with severe cognitive impairment and should
be carefully evaluated by prescribing physicians when treating
older persons with this condition [7,8].
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e46669
For this reason Holmes and colleagues have developed a set of
criteria to identify inappropriate drug treatment, which can be
stopped or should not be started in patients with advanced
dementia [9]. The Holmes criteria were drawn by a consensus
panel of experts, part of the Palliative Excellence in Alzheimer
Care Efforts (PEACE) Program [10], with the purpose to decrease
polypharmacy in the elderly and to reduce the use of medications
that are of minimal benefit or high risk to the patients. Prevalence
and factors associated with use of these drugs have been rarely
evaluated in literature. The aim of the present study was to
evaluate the prevalence and factors associated with the use of
inappropriate drugs, as assessed by the Holmes criteria, in a sample
of NH residents with severe cognitive impairment in Europe.
Methods
Sample and Study Setting
The Services and Health for Elderly in Long TERm care
(SHELTER) study enrolled 4156 NH residents in 57 facilities of 7
European Union (EU) countries (Czech Republic, England,
Finland, France, Germany, Italy, The Netherlands) and 1 non
EU country (Israel). The SHELTER study has been designed to
validate the interRAI instrument for Long Term Care Facilities
(interRAI LTCF), a comprehensive standardized instrument, as
a tool to assess the care needs and provision of care to residents in
NHs in Europe [11]. The study was conducted from 2009 to 2011.
In each country a sample of NHs was identified and invited to
participate to the study. This sample was not randomly selected
and it was not intended to be representative of all NH residents in
each country. A total number of 57 NH facilities participated to
the study, 10 facilities in Czech Republic, 9 in England, 4 in
Finland, 4 in France, 9 in Germany, 7 in Israel, 10 in Italy and 4 in
the Netherlands.
Older adults residing in participating NHs at the beginning of
the study and those admitted in the 3 months enrolment period
following the initiation of the study were assessed using the
interRAI LTCF. In the SHELTER project no exclusion criteria
were adopted. The aim of the present study was to assess use of
inappropriate drugs in a sample of residents with severe cognitive
impairment, defined by a CPS score of 4 to 6, admitted to NHs
participating in the SHELTER project For this reason, from the
initial sample of 4156 residents, those with missing data on
medication use (n = 133; 3.2%), and those without severe cognitive
impairment (defined as CPS,4, n= 2574; 61,9%) were excluded,
leading to a final sample of 1449 NH residents. Ethical approval
for the study was obtained in all countries according to local
regulations. Residents were invited to take part in the study and
were free to decline participation. Consent was obtained with
assurance of data confidentiality.
Data Sources
The InterRAI LTCF contains over 350 data elements including
socio-demographic variables, numerous clinical items about both
physical and cognitive status, as well as all clinical diagnoses, signs,
symptoms, syndromes and treatments provided. The SHELTER
study showed that the interRAI LTCF is a reliable instrument,
which enables the creation of databases that can be used to assess
and compare characteristics of NH residents across countries,
languages and cultures [11].
Study researchers responsible for data collection were trained
following a previously validated procedure [12]. In each country,
training sessions were organised to teach study researchers how to
perform the assessment using the interRAI LTCF, including the
specific forms and appropriate response codes, and to develop care
planning. Study researchers were trained to use a variety of
information sources, such as direct observation, interviews with the
person under care, family, friends, or formal service providers, and
review clinical records, both medical and nursing.
Outcome Measure
As part of the InterRAI LTCF assessment, study researchers
collected information on all drugs used by the residents during the
three days prior to the assessment. Researchers were instructed to
derive drug data from different information sources, including
physician order sheets and medication administration records.
Drug information included non-proprietary and proprietary
name, Anatomical Therapeutic and Chemical code of the WHO
Collaborating Centre for Drug Statistics Methodology [13],
formulation, dosage, frequency (number of times per day, week
or month the medication is taken), and route of administration.
Topical treatments and drugs taken as needed in the three days
prior to the assessment were also recorded.
Inappropriate Drug Use
To identify inappropriate drug use we adopted the criteria
developed and published by Holmes et al. in 2008, which identify
drugs no longer appropriate for patients with advanced dementia.
These criteria facilitate discontinuation of those medications that
no longer conform with the goals of care in patients with advanced
cognitive deficit [9]. Definition of inappropriate drug use in
patients with severe cognitive impairment (based on the Holmes et
al. criteria) includes drugs rarely appropriate (rarely used in
palliative care, likely to be stopped and unlikely to be started) or
never appropriate (drugs with any use in palliative care that should
be stopped or should not be started).
Cognitive Status
The cognitive performance scale (CPS) was used to assess
cognitive status. The CPS combines information on memory
impairment, level of consciousness, and executive function, with
scores ranging from 0 (intact) to 6 (severe cognitive impairment).
CPS scale corresponded closely with scores generated by the Mini-
Mental State Examination and neurological diagnoses of Alzhei-
mer’s disease and other dementias [14]. For the present study, in
line with previous research, we assessed use of inappropriate drugs
in residents with severe cognitive impairment, defined by a CPS
score of 4 to 6 [15].
Independent Variables
The demographic variables included age and gender. Func-
tional status of residents was evaluated by the seven point MDS
Activities of Daily Living (ADL) Hierarchy Scale [16]. The ADL
Hierarchy Scale ranges from 0 (no impairment) to 6 (total
dependence in self-care). Behavioural symptoms were deemed to
be present if the resident exhibited one or more of the following
symptoms in the three days prior to assessment: wandering,
verbally abusive, physically abusive, socially inappropriate behav-
iour and active resistance of care. Falls were defined as a sudden
loss of balance causing the contact of any part of the body above
the feet with the floor occurring in the 90 days before the
assessment. Clinical diagnoses were recorded by study researchers
gathering information from the residents, the general practitioner
and by a careful review of patient clinical documentation and
previous medical history.
Data on participating facilities were collected with the use of
a specifically designed form, which included data on facility
characteristics, staff and process of care. Data on the presence of
Inappropriate Drugs in Elderly Patients
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a geriatrician and a pharmacist in the facility staff as well as the
presence of multidisciplinary team working in the facility were
recorded.
Statistical Analysis
Characteristics of participants were compared using ANOVA
analyses for normally distributed variables, nonparametric Mann–
Whitney U test for skewed variables, and chi-square analyses for
dichotomous variables. Inappropriate drug use (dependent vari-
able) was operationally defined as a dichotomous variable.
Multivariate analysis of this dichotomous outcome (inappropriate
drug use) was performed using logistic regression models with the
generalized estimating equation approach in SAS PROC
GENMOD [17]. The unit of analysis was the individual resident.
The generalized estimating equation method was used to adjust
for the correlation among individuals residing in the same nursing
facility. This approach has been previously used for analysing
clustered data of patients residing in nursing facilities [15,18]. Age,
gender, country and those variables which were associated with
study outcome the univariate analysis with a p#0.10 were
simultaneously entered in the multivariate analysis. Odds ratios
(OR) and corresponding 95% confidence intervals (CI) were
derived from this model.
In addition, in light of recently published data suggesting
a benefit related to the use of anti-dementia drugs in patients with
moderate or severe Alzheimer’s disease [19], additional analyses
were performed after excluding acetylcholinesterase inhibitors and
memantine from drugs in the Holmes list. Analyses were
performed using SAS statistical software, version 8 (SAS Institute
Inc, Cary, NC).
Results
The mean age of the 1449 older NH residents with severe
cognitive impairment was 84.2 (Standard Deviation 8.9) years,
1087 (75.0%) were women. The mean number of drugs used in
this sample was 6.2 (SD 3.3, median 6, IQR 4–8). Inappropriate
drug use was documented in 643 (44.9%) residents. As shown in
Table 1, compared with residents not using inappropriate drugs,
those on inappropriate drugs had a less severe ADL impairment,
a higher rate of falls, were less likely to be long stay residents ($1
year) and had a higher number of comorbidities, including
ischemic heart disease, stroke, diabetes, heart failure and
pneumonia. In addition, residents on inappropriate drugs were
more likely to have experienced a recent hospitalization (in the last
90 days) and less likely to live in a facility which included
a geriatrician among staff relative to those receiving appropriate
treatment.
With regard to appropriateness of drugs prescription according
to CPS score, Figure 1 shows that the prevalence of rarely
appropriate and never appropriate drug prescription varied
according to CPS score (p,0.001). In particular, the prevalence
of use of never and rarely appropriate drugs was lower in residents
with the most severe cognitive impairment (CPS= 6). Table 2
shows the pattern of inappropriate drug use according to the CPS
score. Among rarely appropriate drugs antispasmodics and
digoxin were the most commonly used (6.9% and 5.3% re-
spectively), followed by anticoagulants, alpha-blockers and bispho-
sphonates. Among the never appropriate drugs, lipid-lowering
agents (9.9%) and antiplatelet agents (excluding ASA) (9.9%) were
the most commonly prescribed. Use of acetylcholinesterase
inhibitors and memantine was also common in this sample
(7.2% and 5.3% respectively).
Results of the multivariate analysis are reported in Table 3. Use
of inappropriate drugs (including never and rarely appropriate)
was directly associated with specific diseases including diabetes
(OR 1.64; 95% CI 1.21–2.24), heart failure (OR 1.48; 95% CI
1.04–2.09), stroke (OR 1.43; 95% CI 1.06–1.93), and a recent
hospitalization (OR 1.69; 95% CI 1.20–2.39). An inverse relation
was shown between inappropriate drug use and the presence of
a geriatrician on the staff (OR 0.55; 95% CI 0.39–0.77). Only
stroke was independently associated with the use of never
appropriate drugs (OR 1.50; 95% CI 1.07–2.10). Finally, an
inverse relation was described between likelihood of receiving
inappropriate drug and the severity of functional impairment (OR
0.82; 95% CI 0.71–0.94).
After exclusion of memantine and acetylcholinesterase inhibi-
tors from the list of inappropriate drugs, use of inappropriate drugs
(including never and rarely appropriate) was documented in 540
residents (37.3%). Results of the multivariate analysis showed that
use of inappropriate drugs (as evaluated by these revised criteria)
was associated with diabetes (OR 1.86; 95% CI 1.36–2.54), heart
failure (OR 1.61; 95% CI 1.13–2.30), stroke (OR 1.72; 95% CI
1.27–2.34), recent hospitalization (OR 1.74; 95% CI 1.22–2.48)
and the presence of a geriatrician on the staff (OR 0.64; 95% CI
0.45–0.91).
Discussion
The present study shows that use of inappropriate drugs is
common in NH residents with severe cognitive impairment in
Europe, with about half of the study sample receiving in-
appropriate medications. Comorbidity, a recent hospitalization,
functional impairment and presence of a geriatrician in the facility
were associated with a reduced risk of inappropriate drug use.
Lipid-lowering drugs and antiplatelet agents (but not ASA)
followed by anti-dementia drugs (acetylcholinesterase inhibitors
and memantine) were the most frequently inappropriate drugs
used, followed by antispasmodics, digoxin and anticoagulants.
Use of medications is a fundamental component of the care for
elderly people. The optimization of drug prescribing in this group
of patients has become an important public-health issue world-
wide. The aging process determines an increase of prevalence of
chronic diseases and a progressive deterioration of organ function,
that in turn affect the body’s ability to metabolize medicines.
These alterations change drug pharmacokinetics and pharmaco-
dynamics and increase sensitivity of older patients to adverse drugs
reactions (ADRs) [20,21]. Older adults in NHs usually suffer from
multiple comorbidities, functional and cognitive impairment,
geriatric syndromes and often use polypharmacotherapy. These
factors may influence the efficacy of prescribed drugs and limit
their benefits.
In particular, use of drugs in older adults with severe cognitive
impairment represents a challenging task for prescribing physi-
cians. As mentioned, drugs that may affect cognition or induce
delirium should be avoided when treating patients with co-existing
cognitive impairment [4]. In addition, patients with cognitive
impairment may have communication difficulties and therefore
under-report adverse effects [5,6]. Advanced cognitive impairment
may be associated with feeding problems which make the oral
administration of several medications difficult [22]. Finally,
cognitive impairment is associated with limited life expectancy
and therefore limits the efficacy of pharmacological treatments
and questions the appropriateness of multiple drug use [23,24].
These factors pose a risk for drug related adverse outcomes of
these patients and challenge the physician with difficult ethical
decisions. For each patient with advanced cognitive impairment,
Inappropriate Drugs in Elderly Patients
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a careful evaluation of potential benefits and risks of any
prescribed medication should be performed and unnecessary or
futile pharmacological treatment stopped [7,22].
In agreement with a previous study [3], lipid-lowering agents
were the inappropriate drug most commonly used in our sample.
Use of these drugs might be questionable in a cohort of patients
with end-stage dementia and limited life expectancy when quality
Table 1. Sample characteristics according to inappropriate drug use.
All n =1449 (%)
Inappropriate
Drug Use* n=643 (%)
No Inappropriate Drug
Use n=806 (%) p
Demographics
Age, years (mean6SD) 84.268.9 84.268.2 84.269.6 0.972
Female gender 1087 (75.0) 471 (73.3) 616 (76.4) 0.179
Geriatric conditions
ADL Hierarchy Scale score (mean6SD) 4.761.3 4.661.3 4.961.2 ,0.001
Behavioral symptoms 821 (56.1) 354 (55.1) 458 (56.9) 0.489
Falls 250 (17.4) 132 (20.7) 118 (14.8) 0.004
Long staying (.1 year) 978 (68.8) 417 (65.8) 561 (71.2) 0.029
Comorbidities
Number of diseases (mean 6 SD) 2.661.5 2.861.5 2.461.5 ,0.001
Ischemic heart disease 355 (24.6) 183 (28.6) 172 (21.4) 0.002
Stroke 350 (24.2) 177 (27.6) 173 (21.5) 0.008
Diabetes 283 (19.6) 163 (25.4) 120 (14.9) ,0.001
Heart failure 211 (14.6) 120 (18.8) 91 (11.3) ,0.001
Cancer 133 (9.2) 65 (10.1) 68 (8.5) 0.273
Parkinson’s Disease 122 (8.4) 56 (8.7) 66 (8.2) 0.775
Urinary Tract Infections 100 (6.9) 52 (8.1) 48 (6.0) 0.118
Pneumonia 56 (3.9) 33 (5.1) 23 (2.9) 0.028
Fractures 31 (2.1) 12 (1.9) 19 (2.4) 0.586
Recent Hospitalization{ 201 (13.9) 114 (17.9) 87 (10.8) ,0.001
Facility features
Presence of a geriatrician 866 (59.8) 361 (56.1) 505 (62.7) 0.013
Presence of a pharmacist 454 (31.3) 209 (32.5) 245 (30,4) 0.393
Multidisciplinary Team 1333 (92.0) 592 (92.1) 741 (91.9) 0.926
ADL – Activities of Daily Living.
*includes drugs defined as never or rarely appropriate based on Holmes criteria.
{any hospitalization occurring in the last 90 days before assessment.
doi:10.1371/journal.pone.0046669.t001
Figure 1. Inappropriate drug use according to Cognitive Performance Scale (CPS) score.
doi:10.1371/journal.pone.0046669.g001
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of life is the main focus of care and the benefits of these drugs are
irrelevant. Also use of anti-dementia drugs was common, despite
their benefits in patients with severe dementia are still being
debated [19,25,26]. Recently [26] the DOMINO trial suggested
that in patients with moderate to severe Alzheimer’s dementia
continuing donepezil, as compared with discontinuing it, was
associated with better scores on measures of cognitive ability and
activities of daily living [19]. Notably, only half of the patients who
were assigned to continue donepezil in this trial maintained their
treatment for the entire study period, apparently because of
a perceived lack of efficacy and adverse effects [27].
Almost half of the study participants were receiving inappro-
priate drugs. A possible reason for this finding is the lack of
a systematic recommendation for reducing unnecessary medica-
tions at the end of life, especially those used for the treatment of
chronic diseases. This lack of clear guidance may lead prescribing
physicians to adopt different approaches in such complex patients
[7,22]. While some physicians may believe that pharmacological
treatment must follow recommendations issued for young adults to
provide the best outcomes, others may be concerned regarding
such an approach and believe that drug treatment should be
tailored to residents’ needs, taking into consideration clinical
conditions, but also non clinical factors, including function,
geriatric conditions and life expectancy. Such a comprehensive
approach, traditionally endorsed by geriatric medicine might
result in a reduced number of prescribed drugs and explain the
reduced prevalence of polypharmacy associated with presence of
a geriatrician on the facility staff [28].
In addition, our findings suggest that hospitalization may lead to
an increased use of inappropriate drugs among people with severe
cognitive impairment, and underlie the need for a careful review of
treatments after acute events causing transitions across different
healthcare settings. Indeed, residents admitted to hospital often
have a genuine need for many drugs and may be victim of
a ‘‘prescribing cascade’’ which leads to an increased likelihood of
receiving inappropriate drug therapy. Severe functional impair-
ment in our sample was associated with a reduced rate of use of
drugs classified as never appropriate drugs. This finding may be
related to the lack of data on benefits of pharmacological
treatment in disabled older adults [7,21]. In addition, in pre-
scribing medications the patient’s estimated life expectancy should
be weighed against the time required to achieve benefit from that
treatment. For this reason use of many drugs should be avoided in
disabled NH residents with a limited life expectancy.
In our sample, use of inappropriate drugs seems associated with
a 22% increased rate of falls, but this association does not reach
statistical significance in the multivariate model. The lack of
a significant association might be related to the fact that the effect
of inappropriate drug use on falls is smaller than we can detect.
The present study presents several limitations. First, the severe
cognitive impairment (CPS 4 to 6) as defined by the Cognitive
Performance Scale does not allow us to recognize its cause.
Second, only drugs taken during the three days prior to the
assessment were recorded in the present study. This could lead to
an underestimate of the prevalence of inappropriate drug use
because several drugs may be administered weekly (i.e. bi-
sphophonate). Third, the study sample was not meant to be
nationally representative and therefore results cannot be general-
ized to all NH residents in Europe. Finally, to assess inappropriate
prescribing we used a set of criteria developed in the US, whose
Table 2. Inappropriate drug use according to the Cognitive Performance Scale (CPS) score.
Drug class
All n = 1449
(%)
CPS 4 n=215
(%)
CPS 5 n=694
(%)
CPS 6 n=540
(%) p
Inappropriate Drug (rarely + never appropriate) 643 (44.4) 101 (47.0) 340 (49.0) 202 (37.4) ,0.001
Rarely Appropriate
Antispasmodics 100 (6.9) 15 (7.0) 54 (7.8) 31 (5.7) 0.373
Digoxin 77 (5.3) 15 (7.0) 35 (5.0) 27 (5.0) 0.499
Warfarin 71 (4.9) 8 (3.7) 37 (5.3) 26 (4.8) 0.629
Heparin and Low-weight heparins 43 (3.3) 9 (4.2) 15 (2.2) 19 (3.5) 0.197
Alpha Bockers 41 (2.8) 9 (4.2) 21 (3.0) 11 (2) 0.250
Biphosphonates 40 (2.8) 5 (2.3) 24 (3.5) 11 (2.0) 0.292
Antiarrhythmics 33 (1.5) 0 (0.0) 13 (1.9) 9 (1.7) 0.137
Tamsulosin 20 (1.4) 5 (2.3) 11 (1.6) 4 (0.7) 0.197
Clonidine 17 (1.2) 4 (1.9) 7 (1.0) 6 (1.1) 0.590
Urinary Antispasmodics 10 (0.7) 2 (0.9) 5 (0.7) 3 (0.2) 0.847
Mineralcorticoids 4 (0.3) 2 (0.9) 0 (0.0) 2 (0.4) 0.066
Never Appropriate
Lipid-lowering Medications 143 (9.9) 25 (11.6) 78 (11.2) 40 (7.4) 0.053
Antiplatelets Agents (excluding ASA) 143 (9.9) 10 (4.7) 75 (10.8) 58 (10.7) 0.021
Acetylcholinesterase inhibitors 104 (7.2) 20 (9.3) 67 (9.7) 17 (3.1) ,0.001
Memantine 77 (5.3) 16 (7.4) 48 (6.9) 13 (2.4) 0.001
Immunomodulators 4 (0.3) 3 (1.4) 1 (0.1) 0 (0.0) 0.003
Hormone Antagonists (including antiestrogens) 2 (0.1) 0 (0.0) 2 (0.3) 0 (0.0) 0.336
Cytotoxic chemotherapy 2 (0.1) 0 (0.0) 1 (0.1) 1 (0.2) 0.824
Leukotriene Receptor Antagonists 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0.580
doi:10.1371/journal.pone.0046669.t002
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application to a European population may be questionable
because of potential differences in medication policy and
pharmaceutical marketing.
In conclusion, this cross-sectional study showed that inappro-
priate drug use is common among NH residents and some factors
may help to identify those with advanced dementia who are at
high risk of medication burden. Number of comorbidities, recent
hospitalization and level of disability (evaluated by Activities of
Daily Living Hierarchy Scale) were associated with the use of
inappropriate medications. Finally, the presence of a geriatrician
in the facility was associated with a reduced rate of inappropriate
drug use, suggesting that a geriatric approach can improve quality
of prescribing. Data from this study may be useful to identify
a population at risk of iatrogenic illness because of poor
prescribing and to target interventions aimed at improving quality
of drug use.
Author Contributions
Conceived and designed the experiments: MT ET DF JG HGR FL RL RB
GO. Performed the experiments: ET DF JG HGR GO. Analyzed the data:
GC DLVMT RL GO. Contributed reagents/materials/analysis tools: MT
ET DF JG HGR GO. Wrote the paper: GC GO. Critically revised the
manuscript: ET DF JG HGR RL.
References
1. Magaziner J, German P, Zimmerman SI, Hebel JR, Burton L, et al. (2000) The
prevalence of dementia in a statewide sample of new nursing home admissions
aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in
Nursing Homes Research Group. The Gerontologist.40: 663–72.
2. Doshi JA, Shaffer T, Briesacher BA (2005) National estimates of medication use
in nursing homes: findings from the 1997 medicare current beneficiary survey
and the 1996 medical expenditure survey. Journal of the American Geriatrics
Society. 53: 438–43.
3. Tjia J, Rothman MR, Kiely DK, Shaffer ML, Holmes HM, et al. (2010) Daily
medication use in nursing home residents with advanced dementia. Journal of
the American Geriatrics Society.58: 880–8.
4. Huey ED, Taylor JL, Luu P, Oehlert J, Tinklenberg JR (2006) Factors associated
with use of medications with potential to impair cognition or cholinesterase
inhibitors among Alzheimer’s disease patients. Alzheimers Dement.2: 314–21.
5. Brauner DJ, Muir JC, Sachs GA (2000) Treating nondementia illnesses in
patients with dementia. JAMA. 283: 3230–5.
6. Onder G, Gambassi G, Scales CJ, Cesari M, Vedova CD, et al. (2002) Adverse
drug reactions and cognitive function among hospitalized older adults. Eur J
Clin Pharmacol. 58: 371–7.
7. Fried TR, Tinetti ME, Iannone L (2011) Primary care clinicians’ experiences
with treatment decision making for older persons with multiple conditions. Arch
Intern Med. 171: 75–80.
8. Onder G, Liperoti R, Fialova D, Tosato M, Danese P, et al. (2012)
Polypharmacy in Nursing Home in Europe: Results From the SHELTER
Study. J Gerontol A Biol Sci Med Sci. 6: 698–704.
9. Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, et al. (2008)
Integrating palliative medicine into the care of persons with advanced dementia:
identifying appropriate medication use. Journal of the American Geriatrics
Society. 56: 1306–11.
Table 3. Factors associated with inappropriate drug use.
Never Appropriate Drugs
Inappropriate drug use (Never + Rarely
Appropriate Drugs)
Odds Ratio (95% Confidence Interval)
Demographics
Age (10 yrs increment) 0.91 (0.79–1.05) 1.08 (0.89–1.16)
Female gender 1.15 (0.84–1.57) 0.97 (0.74–1.27)
Long Term Stay 0.89 (0.65–1.20) 0.79 (0.61–1.03)
Geriatric Conditions
ADL hierarchy scale score 0.82 (0.71–0.94) 0.92 (0.81–1.04)
CPS score
4 1 1
5 1.18 (0.80–1.74) 1.06 (0.75–1.51)
6 0.79 (0.50–1.26) 0.77 (0.51–1.71)
Falls 1.22 (0.87–1.70) 1.25 (0.92–1.70)
Comorbidities
Number of diseases 1.04 (0.92–1.17) 1.03 (0.92–1.16)
Ischemic heart disease 1.06 (0.74–1.54) 1.20 (0.87–1.66)
Diabetes 1.39 (0.99–1.93) 1.64 (1.21–2.24)
Heart failure 0.95 (0.64–1.41) 1.48 (1.04–2.09)
Stroke 1.50 (1.07–2.10) 1.43 (1.06–1.93)
Pneumonia 1.29 (0.67–2.47) 1.47 (0.80–2.70)
Recent Hospitalization { 1.08 (0.73–1.60) 1.69 (1.20–2.39)
Facility features
Presence of a geriatrician 0.73 (0.51–1.05) 0.55 (0.39–0.77)
Analyses are adjusted by Country.
ADL – Activities of Daily Living. ADL hierarchical scale score ranges from 0 (no impairment) to 6 (total dependence in self-care).
CPS – Cognitive Performance Scale score.
{Any hospitalization occurring in the last 90 days before assessment.
doi:10.1371/journal.pone.0046669.t003
Inappropriate Drugs in Elderly Patients
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e46669
10. Shega JW, Levin A, Hougham GW, Cox-Hayley D, Luchins D, et al. (2003)
Palliative Excellence in Alzheimer Care Efforts (PEACE): a program description.
Journal of palliative medicine.6: 315–20.
11. Onder G, Carpenter I, Finne-Soveri H, Gindin J, Frijters D, et al. (2012)
Assessment of nursing home residents in Europe: the Services and Health for
Elderly in Long TERm care (SHELTER) study. BMC health services
research.12: 5.
12. Landi F, Sgadari A, Zuccala G, Pahor M, Carbonin P, et al. (1999) A brief
training program on resident assessment instrument improves motivation of
nursing home staff. The journal of nutrition, health & aging. 3: 24–8.
13. Anon. WHOCC - Home. Available at: http://www.whocc.no/.
14. Morris JN, Fries BE, Mehr DR, Hawes C, Phillips C, et al. (1994) The MDS
Cognitive Performance Scale. Journal of Gerontology. 49: 174–182.
15. Teno JM, Mitchell SL, Gozalo PL, Dosa D, Hsu A, et al. (2010) Hospital
characteristics associated with feeding tube placement in nursing home residents
with advanced cognitive impairment. JAMA. 303: 544–50.
16. Morris JN, Fries BE, Morris SA (1999) Scaling ADLs within the MDS. The
journals of gerontology. Series A, Biological Sciences and Medical Sciences.
54(11): M546–53.
17. Hanley JA, Negassa A, Edwardes MD deB, Forrester JE (2003) Statistical
analysis of correlated data using generalized estimating equations: an
orientation. American Journal of Epidemiology. 157: 364–75.
18. Mitchell SL, Teno JM, Roy J, Kabumoto G, Mor V (2003) Clinical and
organizational factors associated with feeding tube use among nursing home
residents with advanced cognitive impairment.JAMA.290: 73–80.
19. Howard R, McShane R, Lindesay J, Ritchie C, Phillips P, et al. (2012)
Donepezil and memantine for moderate-to-severe Alzheimer’s disease.N Engl J
Med. 366: 893–903.
20. Colloca G, Santoro M, Gambassi G (2010) Age-related physiologic changes and
perioperative management of elderly patients. Surgical oncology. 19: 124–30.
21. Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP,
et al. (2010) Development and validation of a score to assess risk of adverse drug
reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk
score. Arch Intern Med. 170: 1142–8.
22. Fusco D, Lattanzio F, Tosato M, Corsonello A, Cherubini A, et al. (2009)
Development of CRIteria to assess appropriate Medication use among Elderly
complex patients (CRIME) project: rationale and methodology. Drugs & Aging.
26 Suppl 1: 3–13.
23. Lee M, Chodosh J (2009) Dementia and life expectancy: what do we know?
Journal of the American Medical Directors Association.10: 466–71.
24. Holmes HM (2009) Rational prescribing for patients with a reduced life
expectancy. Clinical Pharmacology and Therapeutics. 85: 103–7.
25. Sabbagh M, Cummings J (2011) Progressive cholinergic decline in Alzheimer’s
Disease: consideration for treatment with donepezil 23 mg in patients with
moderate to severe symptomatology. BMC neurology. 11: 21.
26. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, et al. (2004)
Memantine treatment in patients with moderate to severe Alzheimer disease
already receiving donepezil: a randomized controlled trial. JAMA. 291: 317–24.
27. Schneider LS (2012) Discontinuing donepezil or starting memantine for
Alzheimer’s disease. N Engl J Med. 366: 957–9.
28. Onder G, Lattanzio F, Battaglia M, Cerullo F, Sportiello R, et al. (2011) The
Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism.
Curr Drug Metab. 12: 647–51.
Inappropriate Drugs in Elderly Patients
PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e46669
